Sandoz, based in Basel, Switzerland, and Canonsburg, Pennsylvania-based Mylan were sued in the U.S. District Court, Southern District of New York (Manhattan) by Teva after they filed with the U.S. Food and Drug Administration for approval of generic drugs to compete with Petach Tikva, Israel-based Teva’s Copaxone, which is prescribed to reduce the frequency of relapses in MS patients. i.
Mylan and Sandoz AG won the dismissal of the lawsuits.
U.S. District Judge Katherine Forrest in Manhattan, granted the drug companies’ motions to dismiss the cases in their entirety, ruling that the generic competitors were using technology that is different from that protected in Teva’s patents.
“Any case or controversy that may have existed at the outset of these cases when filed has been mooted,” Forrest said in her opinion.
The cases are Teva Pharmaceuticals USA v. Sandoz, 09-10112, and Teva Pharmaceuticals v. Mylan Pharmaceuticals, 10-7246, U.S. District Court, Southern District of New York (Manhattan).
This report is based on a report by Bloomberg.